USA flag logo/image

An Official Website of the United States Government

Development of PEDF Protein: An Antiangiogenic Agent

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65559
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
EY014769
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
GENVEC, INC.
65 W WATKINS MILL RD GAITHERSBURG, MD -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2004
Title: Development of PEDF Protein: An Antiangiogenic Agent
Agency: HHS
Contract: 2R44EY014769-02
Award Amount: $775,784.00
 

Abstract:

The leading major causes of blindness in the U.S. are exudative age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR). Both are due to aberrant neovascularization in the eye. PEDF (Pigment Epithelium-Derived Factor) is a potent endogenous antiangiogenic/neurotrophic factor and is considered a key regulator of vascularity in the eye. Compelling data from a variety of investigators indicates that PEDF can inhibit neovascularization in models of human disease. For this SBIR, we hypothesize that direct administration of PEDF protein could be used to treat blinding ocular neovascular diseases such as wet AMD as well as other ocular disorders. Therefore, it is the overall goal of this SBIR Phase II to generate preclinical data enabling clinical testing of PEDF protein. The Specific Aims accordingly are: 1) To test the efficacy of purified human PEDF protein, generated during the SBIR Phase I funded period, in an in vivo experimental ocular disease model; 2) To determine if prolonging PEDF concentrations within the eye by pegylation of PEDF will result in enhanced antiangiogenic activity; and 3) To further advance PEDF protein production/purification methods and assays in preparation of clinical grade material. The results of these studies will be used to decide whether clinical testing of PEDF protein is warranted and if so, provide critical components of the data package necessary for an IND submission.

Principal Investigator:

Lisa L. Wei
2406325539
LWEI@GENVEC.COM

Business Contact:

C. King
2406325537
RKING@GENVEC.COM
Small Business Information at Submission:

GENVEC, INC.
GENVEC, INC. 65 W WATKINS MILL RD GAITHERSBURG, MD 20878

EIN/Tax ID: 232705690
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No